Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | LIPC | P11150 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16750032 | 0.90 | TAAR1 (0.40) | HRH3TAAR1NPC1KDM2BRAB9A | |
| SCHEMBL19939669 | 0.90 | HRH3 (0.42) | HRH3LIPCLIPG | |
| SCHEMBL16996995 | 0.83 | NPC1 (0.34) | HRH3TAAR1NPC1KDM2B | |
| SCHEMBL12026463 | 0.83 | HRH3 (0.33) | HRH3KDM2BKCNH2 | |
| SCHEMBL22251602 | 0.83 | HRH3 (0.33) | HRH3KDM2BKCNH2 | |
| SCHEMBL18501653 | 0.83 | HRH3 (0.34) | HRH3 | |
| SCHEMBL14507941 | 0.80 | HRH3 (0.47) | HRH3 | |
| SCHEMBL26788859 | 0.78 | CTSV (0.35) | HRH3KDM2BRAB9AKCNH2 | |
| SCHEMBL771695 | 0.78 | DRD2 (0.32) | HRH3KDM2BKCNH2 | |
| SCHEMBL18501630 | 0.77 | HRH3 (0.31) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294223-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294223-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | HRH3 1738/4885TAAR1 4749/4885LIPC 2409/4885 |
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | HRH3 1738/4885TAAR1 4749/4885LIPC 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.